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dom from reoperation, and freedom from thromboem-
bolic complications.1-3 However, the appropriateness of
valve repair for patients with rheumatic mitral valve
disease, even when repair appears to be technically fea-
sible, remains controversial.4-6 Our approach has been
M itral valve repair is the procedure of choice inpatients with mitral regurgitation caused by degen-
erative disease. Reparative procedures on degenerative
mitral valves are associated with low operative mortali-
ty and morbidity rates and excellent late survival, free-
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to repair rheumatic mitral valves when the anatomic
substrate appears to permit it. We have reviewed our
17-year single-institution experience with repair and
replacement of rheumatic mitral valves to determine
the late outcomes and advisability of this strategy.
Methods
Patients. From October 1978 to June 1995, 573 patients
underwent mitral valve replacement or repair for rheumatic
disease with Carpentier techniques7-9 at our institution.
Patients undergoing concomitant aortic surgery were exclud-
ed, but patients undergoing concomitant coronary bypass or
tricuspid valve surgery were not. Demographic, intraoperative,
and perioperative outcome data were recorded prospectively.
Demographics. The mean age of the 573 patients was 54 ±
14 years; 81% were female, 55% had congestive heart failure,
22% were undergoing redo mitral valve surgery, and 9% also
underwent coronary bypass. Mitral stenosis was present in
53%, regurgitation in 15%, and both in 32%. Patient demo-
graphics, grouped by the type of surgery performed, are listed
in Table I.
Procedures. Valve repair was performed in 25%, 28% had
a bioprosthesis, and 47% had a mechanical valve. The choice
of procedure varied by the underlying valvular pathology
(Table I).
Follow-up. Follow-up was conducted by mailed question-
naire or telephone interview and by review of the surgeon’s
and cardiologist’s office charts between January 1996 and
April 1997 and was 98% complete. The mean duration of fol-
low-up was 68 ± 46 months. Late survival and valve-related
outcomes were recorded and analyzed as per the specifica-
tions of the Joint Society of Thoracic Surgeons–American
Association for Thoracic Surgery Ad Hoc Liaison Committee
for Standardizing Definitions of Prosthetic Heart Valve
Morbidity.10
Statistical analysis. Data were collected and managed in
dBASE IV data sets and analyzed with SAS and BMDP/DYN
LR statistical analysis software. Univariate analysis of cate-
gorical data was carried out with χ2 or Fisher exact tests.
Univariate analysis of continuous variables was carried out
with analysis of variance or the Student t test. Late survival
and time-dependent morbidity were evaluated univariately by
Kaplan-Meier analysis and multivariately by Cox regression.
We also performed a propensity score analysis to quantify
the probability that a patient might receive a repair versus a
mechanical or bioprosthetic replacement and allow for the
evaluation of potential surgical bias in patient selection on
late outcomes. To do this, we first performed a logistic regres-
sion analysis for the probability that a patient would be
selected to have a valve replacement rather than repair. The
independent predictors of valve replacement were age, coro-
nary artery disease, type of valve pathology, preoperative atri-
al fibrillation, and reoperative mitral valve surgery. This
model had an area under the receiver-operator characteristic
curve of 0.806 and a Hosmer-Lemeshow goodness-of-fit P
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Table I. Patient characteristics
Repair Bioprosthesis Mechanical P value
Demographics
No. of patients 142 162 269
Age (y) 42 ± 1.1 61 ± 1.0 56 ± 0.7 .0001
Sex (% female) 85 77 81 .3
Reoperative mitral surgery (%) 5.6 22 30 .001
Congestive heart failure (%) 53 33 68 .001
Previous CVA/TIA (%) 11 12 20 .02
Preoperative atrial fibrillation (%) 31.7 59.3 67.3 .001
Pathology
Stenosis (n) 96 82 125 .001
Regurgitation (n) 23 31 33
Mixed (n) 23 49 111
Intraoperative
Coronary bypass (%) 2.1 9.9 13 .002
Tricuspid valve surgery (%) 7.8 14 20 .003
CPB time (min) 54 ± 2 77 ± 2 87 ± 2 .0001
XCL time (min) 38 ± 2 54 ± 2 63 ± 2 .0001
Early outcomes
Mortality (%) 0.7 5.6 5.2 .057
Myocardial infarction (%) 0 1.2 1.9 .3
Low output syndrome (%) 18 28 16 .012
Stroke (intraoperative/postoperative) 0/0.7 1.2/0 1.5/0.4 .5
Follow-up (mo) 78 ± 4 84 ± 4 54 ± 2 .0001
Continuous variables are presented as means ± SE. CVA, Cerebrovascular accident; TIA, transient ischemic attack; CPB, cardiopulmonary bypass; XCL, aortic cross-
clamp.
value of .68. The regression coefficients for each independent
predictor were then used to calculate the predicted probabili-
ty of valve replacement for each patient. The natural log of
the probability was calculated as the propensity score.
The Cox regression analyses were then repeated, with the
inclusion of the propensity score as a potential predictor of
late outcomes, to adjust for the bias in selecting a patient for
repair versus replacement. The propensity score did not
emerge as an independent predictor of any of our late out-
comes, suggesting that differences attributed to type of valve
surgery by the initial Cox regression analyses were not
explained by surgical bias in patient selection on the basis of
their preoperative characteristics.
Results
Hospital outcomes. Operative mortality for all 573
patients was 4.2% but was only 0.7% in patients under-
going repair (Table I). Postoperative low output syn-
drome was more prevalent after replacement with a bio-
prosthetic valve (P = .012). There was no statistically
significant difference between groups in the prevalence
of myocardial infarction or perioperative stroke.
Late outcomes
Survival. Overall 5- and 10-year survival was as fol-
lows: valve repair, 97% ± 1.8% and 88% ± 4.5%; bio-
prosthetic valve replacement, 83% ± 3.0% and 70% ±
4.4%; and mechanical valve replacement, 88% ± 2.2%
and 73% ± 6.0% (Fig 1). By Cox regression, the pre-
dictors of late survival in all patients with rheumatic
mitral valve disease were advanced age (hazard ratio
[HR], 1.07; 95% confidence interval [CI], 1.05-1.09; P
= .0001), the presence of coronary artery disease (HR,
2.10; 95% CI, 1.15-3.84; P = .014), and New York
Heart Association symptom class (HR, 1.46; 95% CI,
1.05-2.03; P = .025). The complexity of the mitral
repair procedure required (commissurotomies for
mitral stenosis versus more complex repairs for mitral
regurgitation or mixed stenosis and regurgitation) did
not appear to directly affect long-term survival; within
the 142 patients undergoing mitral repair, the type of
valve pathology (stenosis, regurgitation, or mixed
stenosis and regurgitation) was not significantly related
to late survival (P = .3).
Cardiac death. Five and 10-year freedom from car-
diac death, including valve-related complications, was
as follows: valve repair, 99% ± 1.1% and 94% ± 3.8%;
bioprosthetic valve replacement, 90% ± 2.6% and 84%
± 3.9%; and mechanical valve replacement, 95% ±
1.5% and 86% ± 4.5% (Fig 2). Advanced age was an
independent predictor of cardiac death (HR, 2.46; 95%
CI, 1.76-3.45; P = .0001), whereas mitral valve repair
independently predicted improved survival (HR for
valve replacement rather than repair, 3.34; 95% CI,
1.32-8.45; P = .01).
Nonvalve-related cardiac death. Freedom from car-
diac death, excluding valve-related causes, was predict-
ed by advanced age (HR, 1.06; 95% CI, 1.04-1.09; P =
.0001) and New York Heart Association symptom class
(HR, 2.03; 95% CI, 1.27-3.24; P = .003). The presence
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Fig 1. Survival in 573 patients undergoing mitral valve surgery for rheumatic disease. Rep, Valve repair; Bio, bio-
prosthetic valve replacement; Mech, mechanical valve replacement.
of coronary artery disease (HR, 1.91; 95% CI, 0.89-4.07;
P = .09) and use of a mechanical prosthesis (P = .17) did
not emerge as significant independent predictors.
Valve-related death. Five and 10-year freedom from
valve-related death was as follows: valve repair, 99% ±
1.1% and 99% ± 1.1%; bioprosthetic valve replace-
ment, 96% ± 1.7% and 92% ± 2.8%; and mechanical
valve replacement, 97% ± 1.2% and 95% ± 2.4% (Fig
3). Valve-related death was predicted by advanced age
(HR, 1.08; 95% CI, 1.04-1.13; P = .0001). Type of
valve surgery (repair, bioprosthesis, or mechanical
prosthesis) also emerged in the regression model but
did not reach statistical significance (P = .078).
Reoperation. Five and 10-year freedom from reoper-
ation was as follows: valve repair, 87% ± 3.0% and
72% ± 5.3%; bioprosthetic valve replacement, 94% ±
56 Yau et al The Journal of Thoracic and
Cardiovascular Surgery
January 2000
Fig 2. Freedom from cardiac death in 573 patients undergoing mitral valve surgery for rheumatic disease. Rep,
Valve repair; Bio, bioprosthetic valve replacement; Mech, mechanical valve replacement.
Fig 3. Freedom from valve-related death in 573 patients undergoing mitral valve surgery for rheumatic disease.
Rep, Valve repair; Bio, bioprosthetic valve replacement; Mech, mechanical valve replacement.
2.1% and 69% ± 5.4%; and mechanical valve replace-
ment, 96% ± 1.4% and 95% ± 1.8% (Fig 4). The risk of
reoperation was predicted by bioprosthetic valve
replacement (HR, 4.29; 95% CI, 1.74-10.59; P = .002),
valve repair (HR, 3.40; 95% CI, 1.34-8.60; P = .01),
age (HR, 0.98; 95% CI, 0.96-0.998; P = .03), and
active endocarditis (HR, 8.93; 95% CI, 1.16-68.7; P =
.04).
Of the 142 patients undergoing valve repair, 23
(16%) patients underwent subsequent reoperation, with
no deaths. The nature of the mitral pathology at the ini-
tial operation and therefore the complexity of the repair
required (simple commissurotomy for isolated mitral
stenosis versus more complex repairs of regurgitant or
mixed lesions) were associated with the risk of late
reoperation. Five-year freedom from reoperation was
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Fig 4. Freedom from reoperation in 573 patients undergoing mitral valve surgery for rheumatic disease. Rep,
Valve repair; Bio, bioprosthetic valve replacement; Mech, mechanical valve replacement.
Fig 5. Freedom from thromboembolic events in 573 patients undergoing mitral valve surgery for rheumatic dis-
ease. Rep, Valve repair; Bio, bioprosthetic valve replacement; Mech, mechanical valve replacement.
93% ± 2.9% for stenotic valves (67% of patients), 82%
± 8.1% for regurgitant valves (17% of patients), and
94% ± 5.4% for valves with mixed stenosis and regur-
gitation (16% of patients) (P = .012).
Thromboembolic events. Five and 10-year freedom
from thromboembolic complications was as follows:
valve repair, 93% ± 2.3% and 93% ± 2.3%; biopros-
thetic valve replacement, 94% ± 1.9% and 93% ±
2.2%; and mechanical valve replacement, 89% ±
2.5% and 72% ± 6.7% (Fig 5). Thromboembolic com-
plications were predicted by type of use of a mechan-
ical prosthesis (HR, 6.91; 95% CI, 2.94-16.25; P =
.0001), advanced age (HR, 1.05; 95% CI, 1.02-1.09; P
= .0006), and active endocarditis (HR, 17.3; 95% CI,
2.15-139; P = .007). The presence of coronary artery
disease (HR, 2.27; 95% CI, 0.95-5.46; P = .066) and
the type of mitral valvular lesion (stenosis, regurgita-
tion, or mixed stenosis and regurgitation; HR, 1.42;
95% CI, 0.98-2.06; P = .067) did not reach statistical
significance as predictors of thromboembolic events.
Endocarditis. Five and 10-year freedom from
repaired native or prosthetic valve endocarditis was as
follows: valve repair, 99% ± 0.8% and 98% ± 1.3%;
bioprosthetic valve replacement, 98% ± 1.1% and 97%
± 1.6%; and mechanical valve replacement, 99.6% ±
0.4% and 97% ± 2.2% (P = .8).
Total valve-related morbidity. Five and 10-year free-
dom from valve-related morbidity (thromboembolic
events, endocarditis, or reoperation) was as follows:
valve repair, 86% ± 3.1% and 71% ± 5.3%; biopros-
thetic valve replacement, 91% ± 2.5% and 62% ±
5.4%; and mechanical valve replacement, 87% ± 2.8%
and 64% ± 6.3% (P = 0.3).
Discussion
Over the last 2 decades, our institutional practice in
patients undergoing mitral valve surgery for rheumatic
disease has evolved from predominant implantation of
bioprosthetic valves in the 1970s to a more aggressive
strategy of mitral valve repair, starting in the early 1980s,
whenever the valvular anatomy appeared to allow cor-
rection of the hemodynamic abnormalities. Over time,
mechanical prostheses have largely supplanted biopros-
thetic valves in the mitral position. However, we have
noted a 10-year survival rate of only 73% ± 6.0% at 10
years after implantation of a mechanical mitral prosthe-
sis, a figure consistent with most published series.11-13
This late mortality is attributed largely to thromboem-
bolic events and bleeding complications of long-term
anticoagulation. Although lower intensity anticoagula-
tion with the St Jude Medical bileaflet valve may be pos-
sible, late mortality and morbidity rates remain substan-
tial and have led to persistent interest in defining a sub-
set of patients with rheumatic mitral valvular pathology
in whom repair may yield better long-term out-
comes.5,6,14 These considerations prompted us to review
the long-term results of our current operative strategies
in patients with rheumatic mitral valve disease.
Late consequences of mitral valve repair. In the
carefully selected patients in whom valve repair was
performed, we noted an 88% 10-year survival rate
compared with a 70% rate for bioprostheses and a 73%
rate for mechanical valves. This difference may be par-
tially accounted for by the lower mean age of the
patients undergoing repair. We were more aggressive in
performing repairs in young patients in order to avoid
decades of anticoagulation. However, Cox regression
analysis identified mitral repair as a predictor of better
cardiac survival independent of age. Therefore the ben-
eficial effect of valve repair is not due to its being per-
formed in younger patients. In addition, patients under-
going mitral repair were less likely to be in atrial
fibrillation or to have had a previous stroke or transient
ischemic attack. The propensity score analysis was per-
formed to permit evaluation of the effect of type of
valve surgery independent of these differences in base-
line characteristics, and the results of this analysis sug-
gest that the greater cardiac survival after mitral valve
repair was again independent of the differences in age,
atrial fibrillation, and previous stroke.
Mitral valve repair was also associated with excellent
freedom from thromboembolism but only a 72% free-
dom from reoperation at 10 years. Reoperation, the
major liability of an aggressive strategy of valve repair,
was required in 23 patients and was accomplished
without mortality. The observation that reoperation did
not carry a demonstrably increased risk of death in this
series favors a strategy of repair in selected patients.
This approach would obviously not be appropriate,
however, if reoperation was associated with significant
additional mortality or morbidity. At the time of reop-
eration, however, patients were much more likely to
receive a mechanical valve to minimize the chance of
requiring a third operation.
Mechanical valves were associated with high and
ongoing rates of thromboembolic and bleeding compli-
cations. In this series implantation of a mechanical
valve was the most significant independent predictor of
subsequent thromboembolic events but also the most
significant predictor of freedom from reoperation.
Mechanical valves were associated with decreased
freedom from both valve-related death and nonvalve-
related cardiac death, but these associations were not
statistically significant.
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Selection of patients for repair
Rheumatic mitral stenosis. Patients with rheumatic
stenotic mitral valves with low echocardiographic
scores are ideal candidates for percutaneous balloon
valvotomy.15-17 Excellent short-term and long-term
outcomes have been reported by various groups treat-
ing patients with primarily rheumatic mitral stenosis.
Our approach would be to palliate these patients with
percutaneous balloon valvotomy, reserving operation
for patients with more advanced disease.
Patients with moderate distortion of mitral valvular
anatomy but in whom the anterior leaflet and chordae
tendineae still appear pliable should undergo surgical
exploration to determine whether repair is feasible. The
thickness of the valve leaflets and the presence of chor-
dae tendineae determine the ability to repair the stenot-
ic rheumatic mitral valve. Patients in whom the papil-
lary muscles are fused directly to the free margin of the
valve leaflets should undergo valve replacement rather
than repair.
The appearance of a severely distorted valve on pre-
operative echocardiography, however, portends a near-
ly certain requirement for valve replacement. In addi-
tion, patients with combined aortic and mitral disease
have poor outcomes after either aortic valve repair18 or
mitral valve repair,4 and in most patients with multiple-
valve disease, we would favor valve replacement.
In patients with borderline valvular anatomy, valve
repair may also be favored for nonanatomic considera-
tions, primarily contraindications to long-term antico-
agulation. Conversely, valve replacement may be
favored in patients in whom long-term anticoagulation
will be necessary for other indications. However, valve
repair even in a subset of these patients may allow
lower intensity anticoagulation and perhaps a reduction
in bleeding complications.
Rheumatic mitral regurgitation.The risk of reopera-
tion after repair for rheumatic mitral regurgitation may
be related to patient age and to the presence of active
rheumatic carditis.5,19 In young Saudi patients present-
ing with a dilated anulus, thickened but mobile leaflets,
and somewhat thickened and elongated chordae but
without severe commissural fusion and subvalvular
fibrosis, Gometza and colleagues20 reported an actuar-
ial survival rate of 98% ± 2% at 78 months after repair
compared with only 75% ± 19% at 48 months after
replacement. However, 37% of patients undergoing
repair required reoperation, with 81% of reoperations
required within the first year.
In older patients (mean age, 55 years) with isolated
rheumatic mitral regurgitation or mixed regurgitation
and stenosis, Grossi and colleagues4 reported a 92%
freedom from reoperation at 8 years in patients receiv-
ing a St Jude Medical valve compared with 86% for
patients undergoing repair. This difference was not sta-
tistically significant, but this was felt to be due to the
small number of patients followed to that interval.
The failure of mitral valve repair in patients with
rheumatic mitral regurgitation appears to be more often
valve related (including progressive primary valve dis-
ease, endocarditis, or leaflet retraction) than procedure
related (ie, suture dehiscence, rupture of previously
shortened chordae, or incomplete initial correction).21
Mixed rheumatic mitral stenosis and regurgitation.
Mixed mitral stenosis and regurgitation caused by
rheumatic disease may increase the risk of reoperation
after repair. Fernandez and colleagues22 reported that
freedom from reoperation after valve repair was 90% at
5 years and 80% at 8 years in patients who had either
pure mitral regurgitation or isolated mitral stenosis, but
patients with mixed mitral stenosis and regurgitation
had only an 80% freedom from reoperation at 5 years
and 72% at 10 years. We did not note an increased
propensity to failure after repair of valves with a com-
bination of stenosis and regurgitation in our series
(94% ± 5% freedom from reoperation at 5 years), but
the number of patients in this category was small.
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Discussion
Professor Alain F. Carpentier (Paris, France). This is an
important paper because if there is little doubt as to the ben-
efit of valve repair in congenital or degenerative valvular dis-
ease, recent papers have questioned the interest of valve
repair in rheumatic valvular disease.
The authors report a 72% freedom from reoperation at 10
years, and whenever a reoperation was necessary, a 0% oper-
ative mortality rate. There was a striking difference in patient
survival between valve repair and valve replacement, with
88% versus 72% survival rates at 10 years, respectively. The
authors underlined some demographic differences between
the 2 groups that favor the valve-repair group. I wonder
whether these differences could play a significant role
because my own experience with a larger series and more
similar groups confirms that valve repair with the techniques
we use is superior to valve replacement. In our experience the
freedom from reoperation was 79% at 10 years and 76% at 13
years, a striking difference with other series reported in the
literature by authors advising valve replacement rather than
valve repair in rheumatic valvular disease. This difference, I
think, is not due to different types of patient population but to
different types of repair operation.
To see whether we can further reduce the incidence of
reoperation, it is interesting to discuss the most frequent caus-
es of reoperation. In our experience they were as follows:
anulus dilatation (16%), valve stenosis (16%), leaflet retrac-
tion (32%), and leaflet prolapse (36%).
Anulus dilatation is due to a persistent process of anulus
distention when no ring was used at the first operation. The
simple means to avoid this is to systematically use a pros-
thetic ring even when a quadrangular resection of the poste-
rior leaflet has been performed. It is important to use large
prosthetic rings in rheumatic valvular disease to compensate
for the increased rigidity of the leaflets and to reduce the inci-
dence of recurrent stenosis. To do so, one should perform a
leaflet extension of either the anterior, the posterior, or both
leaflets using glutaraldehyde-treated autologous pericardium.
Leaflet extension allows selection of a 1 to 2 size larger ring.
I would like to ask the authors whether they have correlated
the incidence of recurrent stenosis to the size of the rings used
and whether they were able to note that the smaller the ring
implanted, the higher the chance of recurrent stenosis in
rheumatic valvular disease.
Another cause of reoperation is recurrent leaflet prolapse.
How often did the authors find it and what were the mecha-
nisms involved, chordal rupture or failure of a previous
chordal shortening? Because I am responsible for having
introduced the technique of chordal shortening more than 2
decades ago, I would like to underline a possible cause of
failure associated with this technique. The technique consists
in burying the extra length of the chords in a longitudinal
trench created in the papillary muscle. A secondary chordal
rupture can occur whenever the suture used to close the
trench is close to the shortened chords, thus leading to
chordal abrasion. We therefore recommend placing this
suture at a distance from the chords. Since taking this pre-
caution, we have not seen this complication.
Finally, I would like to ask the authors what their current
policy is concerning the use of valve repair versus valve
replacement in rheumatic valvular disease. In light of the
excellent results you presented, do you envision enlarging
your indications? In our own experience, particularly at the
Vietnam Heart Institute, thanks to a larger use of leaflet
extension, the proportion of valve repair versus valve replace-
ment has increased up to 85% in rheumatic valvular disease.
Dr Yau. Thank you, Professor Carpentier, for your kind
comments. As to the comparability of these various groups,
this is obviously a retrospective analysis of patients operated
on over a 17-year time period. We did identify, by means of
Cox regression analysis, that late cardiac survival was favor-
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ably influenced by mitral valve repair independent of the
other potentially confounding factors.
As you have noted, the patients who were undergoing
repair were a very select patient population, younger and
less likely to undergo reoperative surgery and less likely to
have had a stroke or atrial fibrillation preoperatively. The
Cox regression analysis did allow us to identify the type of
valve surgery as a favorable independent predictor of late
cardiac survival. Independent of those things, however,
it is clear that in a retrospective analysis such as this, it
would be impossible to exclude the effect of other un-
known, confounding variables. From the data that we
have, I think that we can certainly strongly support the
approach that we have had at our institution over the pre-
ceding years, that is, to repair a selected subset of these
patients with rheumatic mitral valve disease. This in and of
itself cannot necessarily support a call for expanded indi-
cations for mitral valve repair, although that is certainly
our personal bias.
As far as the incidence of stenosis and possible correlations
with the size of the annuloplasty ring, in this case not all of
our patients had continuing annual echocardiograms, and
therefore our primary indication of failure in many of the
patients who underwent repair was reoperation. In the small
number of patients who underwent reoperation, we were not
able to correlate size of the annuloplasty ring with the subse-
quent development of mitral stenosis.
As far as our current recommendations for mitral repair in
this population, for patients with rheumatic mitral stenosis, I
think we would certainly agree that patients with low
echocardiographic scores and relative preservation of normal
mitral anatomy should undergo a percutaneous valvotomy.
Patients with moderate distortion of mitral anatomy should,
at the time of surgery, undergo exploration for possible repair,
and if the anterior leaflet and chordae are relatively preserved
and reasonably pliable, then we would certainly favor a strat-
egy of repair in those patients. We would reserve replacement
with a mechanical prosthesis for patients in whom we felt the
anatomy was unsuitable for repair and less commonly for
patients with mixed stenosis and regurgitation. As you saw in
our series, mixed stenosis and regurgitation was generally
associated with mechanical valve replacement, and valve
repair has been reported by some authors, notably Fernandez
and colleagues, to result in inferior late outcomes in these
patients. The combination of aortic and mitral pathology
would generally, in our opinion, also constitute an indication
for valve replacement rather than repair.
Dr Lawrence I. Bonchek (Lancaster, Pa). I would like to
draw attention to your emphasis on the fact that the throm-
boembolism rate was much higher in the prosthesis group
than in the repair group.
You mentioned a lot of confounding variables, including
presumably atrial fibrillation, that did not correlate with post-
operative death, but did you correlate the incidence of atrial
fibrillation with the incidence of thromboemboli in both
groups? Although things went by rather quickly, it was quite
apparent that the repair group had a much lower incidence of
preoperative atrial fibrillation, and if that persisted postoper-
atively, the lower incidence of atrial fibrillation in the repair
group would be associated with a lower incidence of throm-
boemboli. Thus the prosthesis in the other group would not
necessarily be the cause of their higher thromboembolic com-
plication rate. 
Dr Yau. Absolutely. As you noted, the incidence of preop-
erative atrial fibrillation in the patients undergoing mitral
repair was about 32% and was significantly higher, about
66%, in the patients undergoing replacement with a mechani-
cal valve. We did, in fact, in the Cox regression analysis for
late thromboembolic events enter preoperative atrial fibrilla-
tion and preoperative cerebrovascular events into that model,
but they did not emerge as statistically significant predictors
of late outcomes.
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